| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.052 | 0.1 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.1 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | 0.05 | 0.1 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.053 | 0.2 |